The facility is now processing a diverse portfolio of compounds, including Sermorelin, BPC-157, and various other high-demand peptides. By focusing on pharma-grade quality rather than lower-cost research materials, Vector anticipates securing an 80% margin on its sales. The operational shift required an exhaustive validation process, spanning equipment calibration, air quality control in Class 5 cleanrooms, and the finalization of standardized production protocols.
In section Releases
Vector Science & Therapeutics Launches Peptide Production in Mequon
With 55,000 vials already pre-sold, Vector Science & Therapeutics has activated the first of four manufacturing suites at its Mequon facility. The milestone marks the company’s transition to full-scale, pharma-grade peptide production, meeting strict cGMP, FDA, and ISO quality benchmarks right on schedule.
Looking ahead, the company plans to bring the remaining three suites online by late September 2026. This expansion is designed to lift total monthly capacity to 800,000 vials. Management expects to scale production to 200,000 vials per month within the next quarter, supported by a major customer commitment of equal volume. Every batch produced undergoes independent verification by Verlytix to ensure compliance with sterility, potency, and purity standards.
Comments (0)
No comments yet. Be the first!